Comparing two drug combinations for advanced NK/T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial compares two treatment combos for newly diagnosed, advanced NKTCL. It tests a new combination (chidamide plus an immunotherapy drug and pegaspargase) against a standard regimen (DDGP) to see which works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of lymphoma called extranodal natural killer/T-cell lymphoma (NKTCL).
- You have not had any previous lymphoma treatment.
- You are between 14 and 70 years old.
- Your lymphoma is stage III or IV (it has spread beyond the original site).
- You are generally well enough to manage daily activities (ECOG score 0-2).
- Your blood counts, liver and kidney function are within acceptable range for this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares an immunotherapy approach to standard chemotherapy as a first step before stem cell transplant for patients with advanced NK/T-cell lymphoma. It aims to see which treatment helps patients better before their own stem cells are transplanted.
This trial tests a combination of an immunotherapy drug (PD-1 antibody, which helps your immune system fight cancer) and radiation therapy for people with early-stage nasal-type NK/T-cell lymphoma. It aims to see if this approach is safe and effective as a first treatment.
This Phase 2 trial tests whether combining sintilimab (an immunotherapy) with chidamide (an anticancer “epigenetic” drug) can shrink peripheral T-cell lymphoma that has come back or didn’t respond. It’s for adults who have measurable lymphoma spots and can safely take both medicines.
This trial compares a new targeted drug combined with standard chemotherapy and an immunotherapy drug against the standard chemo-immunotherapy alone, for people with advanced or non-nasal NK/T-cell lymphoma who haven't been treated yet. The goal is to see if adding the targeted drug improves outcomes.
This study tests a new combination of three drugs (golidocitinib, pegaspargase, and an immune checkpoint inhibitor) as the first treatment for advanced extranodal natural killer/T-cell lymphoma. The goal is to see if this combination can shrink or eliminate the cancer and improve outcomes.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
Hear when a new Extranodal Natural Killer T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.